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ABSTRACT 
Hepatocyte transplantation is an experimental treatment for patients with end-stage liver 
disease and inborn metabolic liver disorders. Studies in animal models and human trials have 
shown that allogenic hepatocytes infused through the portal vein physiologically integrate 
into the liver parenchyma, replacing missing liver function. Current research data provide a 
proof of principle for clinical hepatocyte transplantation in a wide range of liver diseases. 
However, most patients ultimately undergo whole organ liver transplantation due to 
insufficient graft function. Thus, the efficacy and long-term results of clinical hepatocyte 
transplantation must be improved before this treatment can be introduced into routine clinical 
care. 
The present thesis summarizes experimental and clinical studies with the general aim of 
identifying current limitations and improving outcomes of hepatocyte transplantation.  
Paper I investigates strategies for improving short-term preservation of isolated human 
hepatocytes. Human hepatocytes are usually cold stored for prolonged periods between 
isolation and infusion. We found that isolated human hepatocytes undergo cell death and lose 
hepatocyte-specific function during this cold storage period. An alternative technique of liver 
tissue storage and repeated isolations led to improved viability and function of isolated 
hepatocytes before infusion.  
In Papers II and III, a hepatocyte transplantation model was established in the ApoE knockout 
mouse. Clinically relevant animal models are necessary for developing new treatment 
strategies. The ApoE knockout mouse is an ideal model of an inherited metabolic liver 
disease. ApoE is mainly produced by hepatocytes and its deficiency results in extrahepatic 
disease. ApoE (−/−) mice display severe hypercholesterolemia leading to premature 
atherosclerosis. We observed that transplanted wild-type hepatocytes integrated into the liver 
and excreted ApoE, and that this serum ApoE correlated with hepatic donor cell engraftment. 
Transplantation without preconditioning treatment resulted in serum ApoE levels of 1–2% of 
wild-type levels, which did not affect hypercholesterolemia. However, pretreatment with 
retrorsine gave donor hepatocytes a growth advantage, resulting in progressive repopulation 
of up to 55% of the recipient liver. This increased repopulation by donor hepatocytes led to 
normalization of hypercholesterolemia and prevention of atherosclerosis. 
Paper IV evaluated the safety and efficacy of partial hepatectomy preconditioning with 
hepatocyte transplantation in two patients with Crigler-Najjar syndrome type I. Partial 
hepatectomy in combination with hepatocyte transplantation was safe and induced  a 
regenerative response. Serum bilirubin decreased to approximately 50% of pretransplant 
concentrations, and allograft function was further confirmed by detection of bilirubin 
diglucuronides in bile after transplantation. However, both patients lost graft function in 
association with the emergence of donor-specific HLA antibodies. 
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  1 
1 INTRODUCTION 
 
1.1 HEPATOCYTE TRANSPLANTATION 
The first attempts of hepatocyte transplantation were performed in animal models in the 70´s. 
Rugstad et al. reported transplantation of hepatoma cell lines into the Gunn rat, a model of 
Crigler-Najjar syndrome type I (CN-I) (1). CN-I is a rare inborn metabolic liver disease 
caused by deficiency of the hepatic enzyme uridine diphosphoglucuronate 
glucuronosyltransferase 1A1 (UGT1A1). If untreated, UGT1A1 deficiency results in fatal 
brain injury due to unconjugated hyperbilirubinemia. Rugstad et al. demonstrated that 
UGT1A1 enzyme activity could be transferred to the Gunn rat, improving 
hyperbilirubinemia. This was the first reported use of cell transplantation to ameliorate a 
metabolic liver disease. Matas et al. refined these early findings by transplanting 
mechanically isolated liver fragments to the Gunn rat with similar results (2). The first true 
hepatocyte transplantation was performed by Groth et al. who used collagenase perfusion to 
isolate hepatocytes from wild-type Wistar rats and infused these isolated hepatocytes into the 
portal vein of the Gunn rat. They demonstrated that transplantation of only 0.2% of the liver 
mass led to a 40% decrease in serum bilirubin (3, 4). 
In the 1990s, the first successful clinical hepatocyte transplantations were performed (5, 6). 
Liver transplantation was already considered the only curative treatment for many patients 
with end-stage liver disease, acute liver failure, and many forms of metabolic liver diseases 
(7, 8). Over the following decades, results of whole liver transplantation have improved 
dramatically. However, the procedure still carries substantial morbidity and mortality. 
Hepatocyte transplantation has been proposed as an alternative treatment as it has a number 
of potential advantages compared to whole organ transplantation. Importantly, the hepatocyte 
transplantation procedure is less invasive with lower morbidity and mortality (9). 
Hepatocytes also have enormous proliferative potential and a small proportion of the liver 
mass can repopulate an entire liver in cases where the donor cells have a growth advantage 
over the native hepatocytes (10-13). For many of its functions, the liver has an overcapacity 
and replacement of a small fraction of the missing function is often sufficient to improve or 
even correct the underlying disease (6, 14, 15). One donor liver can provide enough cells for 
several recipients, improving the mismatch between the available organs and recipients on the 
waiting list (16). Moreover, in contrast to whole organs, hepatocytes can be cryopreserved 
and are available on demand (5, 9, 17, 18). Finally, in cases of hepatocyte transplantation, the 
patient keeps their own liver as a back-up in the event of graft failure or the future availability 
of better therapies.  
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 2 
1.1.1 Hepatocyte isolation 
Techniques for isolating viable hepatocytes from liver tissue were crucial for the 
development of hepatocyte transplantation. However, the pivotal studies were performed in 
the pancreas rather than the liver. In 1967, Lacy et al. reported the use of collagenase 
perfusion to isolate islets of Langerhans from a rat pancreas (19). Transplantation of these 
islets to diabetic animals resulted in hyperglycemia normalization, paving the way for clinical 
islet transplantation (20). This collagenase perfusion method was later adopted by Berry et al. 
for isolating viable hepatocytes from rat liver (21, 22) and was subsequently further refined 
for isolation of human hepatocytes by Strom et al. (23).  
Today, the isolation process is still based on the same principles with minor modifications. 
Liver tissue is perfused through catheters sutured into the main hepatic vessels—either portal 
or hepatic veins. Perfusion is performed with three solutions. The first solution contains 
EGTA, an iron chelator that removes calcium and thus disrupts intercellular connections. The 
second is a buffered electrolyte solution that removes EGTA as calcium is needed for 
adequate collagenase function. The third solution contains a collagenase-digesting 
extracellular matrix. Perfusion solutions are preheated to 37°C and often the liver is 
maintained at 37°C to optimize enzymatic function. In contrast to in islet isolation, the liver 
tissue is continuously perfused. Complete digestion usually requires 15–35 minutes of 
collagenase perfusion. The liver capsule is cut and the cell suspension is released into ice-
cold medium. Finally, the hepatocytes are washed and purified by low-speed centrifugation. 
The quality of the utilized collagenase is a main factor determining isolation success. Most 
commercially available collagenases are derived from Clostridium histolyticum. These crude 
enzymes have the advantage of high potency, but at the cost of great variability of enzyme 
activity from batch to batch. Furthermore, the bacterial origin with large amounts of 
endotoxins and culture conditions can be controversial if the collagenase is to be applied for 
clinical isolations under good manufacturing practice (GMP) conditions. A highly purified, 
defined, and GMP-approved enzyme (CIzyme™,Vitacyte) has recently become available for 
clinical hepatocyte isolations (24). 
 
1.1.2 Characterization of hepatocyte function and viability 
Hepatocyte transplantation outcome depends on the quality of the isolated hepatocytes (25). 
Hepatocytes participate in a wide variety of functions, including detoxification, glycogen 
storage, bile production and excretion, production of coagulation factors, ammonia 
metabolism, serum protein production, lipoprotein metabolism, etc. Most of these functions 
can be tested in vitro. However, there remains a need to evaluate the significance and cut-off 
values of each individual assay as well as the ability to predict post-transplantation outcome. 
The trypan blue exclusion test is the most commonly used assay and is the only assay 
demonstrated to predict outcome after hepatocyte transplantation (25). This assay evaluates 
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1.1.2 Characterization of hepatocyte function and viability 
Hepatocyte transplantation outcome depends on the quality of the isolated hepatocytes (25). 
Hepatocytes participate in a wide variety of functions, including detoxification, glycogen 
storage, bile production and excretion, production of coagulation factors, ammonia 
metabolism, serum protein production, lipoprotein metabolism, etc. Most of these functions 
can be tested in vitro. However, there remains a need to evaluate the significance and cut-off 
values of each individual assay as well as the ability to predict post-transplantation outcome. 
The trypan blue exclusion test is the most commonly used assay and is the only assay 
demonstrated to predict outcome after hepatocyte transplantation (25). This assay evaluates 
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cell membrane integrity as dead cells are stained blue. It has the advantages of being fast and 
easy to perform and of providing additional morphological information if performed under a 
microscope. The limitation of this assay is that it cannot detect early apoptotic cells. 
Apoptosis can be evaluated using TUNEL staining or evaluation of caspase activity (see 
methodology). 
Another assay commonly used to evaluate hepatocyte function is plating efficiency (PE), 
which tests the ability of single hepatocytes to attach to an extracellular matrix, e.g., collagen, 
laminin, fibronectin, or Matrigel. Hepatocytes rely on cell anchorage, an active process 
requiring cellular receptors, including integrins and cadherins (26, 27). The assay purportedly 
measures the ability of hepatocytes to engraft after transplantation, although this has not been 
confirmed in animal studies (24). 
Another important hepatic function is the urea cycle, in which neurotoxic ammonia is 
converted into urea. Urea cycle deficiencies exist in patients with urea cycle defects or acute 
liver failure, which are both indications for hepatocyte transplantation. Ammonia metabolic 
ability can be measured in hepatocyte cultures by adding ammonia to the cell culture media 
and measuring its disappearance (see methodology).  
Several other main hepatic functions—including production of steroids, bile, vitamin D, and 
cholesterol, as well as the metabolism of many drugs—are catalyzed by enzymes belonging 
to the cytochrome P450 (Cyp450) family. The Cyp450 family comprises heme-containing 
enzymes that give the liver its color as they absorb light with a peak at 450 nm (28-30). This 
enzyme family shows inter-individual and inter-species variations in expression and function, 
and has thus been a main target in pharmacological research (31). Consequently, a wide range 
of assays have been developed to study their activity in vitro (32) (see methodology). 
 
1.1.3 Route of administration 
Clinical hepatocyte transplantations have been performed using three different transplantation 
sites: liver, spleen, and peritoneal cavity. The most common option is to transplant cells into 
the liver by infusing the cells into the portal vein. Portal vein access can be accomplished via 
an ultrasound-guided percutaneous trans-hepatic route or with open surgical access through 
the umbilical vein or a mesenteric vein (9). An advantage of transplanting cells into the liver 
is that donor hepatocytes physiologically integrate with the liver parenchyma. After 
integration, donor cells are histologically indistinguishable from recipient hepatocytes and 
can proliferate and repopulate the host liver driven by local growth factors and cytokines 
(33).  
Much remains unknown regarding the integration process of donor hepatocytes building 
intercellular connections with host hepatocytes, and connecting with the biliary tree and 
vascular system. Animal experiments have shown that hepatocytes infused into the portal 
vein are embolized into the terminal portal vein radicles and sinusoids (33-35), leading to 
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increased portal pressure and small infarcts in the liver parenchyma. Due to their size, the 
infused hepatocytes are usually not dislodged to the pulmonary arteries, although lung 
embolization was described in one patient with acute on chronic liver failure due to 
portocaval shunts (36, 37). The endothelium is disrupted and donor hepatocytes can be found 
in the parenchyma 24 hours after infusion (34). A major proportion of infused cells are 
cleared by macrophages within these first 24 hours. After 3–7 days, the remaining donor 
hepatocytes start to integrate and the liver parenchyma is remodeled. During this time period, 
increased expression of vascular endothelial growth factor (VEGF) and matrix 
metalloproteases are observed in the vicinity of donor hepatocytes (34, 35, 38). The major 
disadvantage of transplanting hepatocytes through the portal vein is the limited cell number 
that can be infused during a single transplantation event without causing portal thrombosis. 
The spleen is also sometimes used as a transplant site, especially in liver cirrhosis patients 
with extensive portocaval shunts and liver scar tissue limiting donor cell engraftment. Cells 
can be transplanted to the spleen by infusion into the splenic artery or by direct puncture of 
the spleen. Interestingly, donor hepatocytes have shown long-term engraftment in the spleen 
and can even proliferate and repopulate the spleen. However, only a limited number of cells 
can be infused, and hepatocyte transplantation to the spleen carries an increased risk of 
bleeding and splenic infarcts (5, 39). 
The peritoneal cavity is another attractive site for clinical hepatocyte transplantation. This site 
allows easy access and transplantation of a large number of cells during a single 
transplantation. It is especially useful for patients with acute liver failure who are in need of 
temporary support until the native liver regenerates.  
Experimental animal studies have also investigated alternative transplantation sites, including 
the kidney capsule, subcutaneous space, intramuscular, and lymph nodes (40-44). 
  
1.1.4 Indications for human hepatocyte transplantation 
Hepatocyte transplantation has been performed experimentally for three main indications: as 
a bridge to liver transplantation in patients with end-stage liver disease, as treatment for 
patients with acute liver failure without organ transplantation, and as treatment for patients 
with inborn metabolic liver diseases.  
Eighteen centers worldwide have reported human hepatocyte transplantations, and the 
literature includes reports of 100 patients undergoing this procedure: 37 patients with 
metabolic liver diseases, 46 with acute liver failure, and 17 with end-stage liver cirrhosis (45). 
In all cases, hepatocyte transplantation has been investigated in a small clinical series or is 
described in a case report. To date, seven centers are actively recruiting patients for this 
procedure: Children’s Hospital University of Pittsburgh, Pennsylvania, USA; King’s College 
London, Great Britain; Cliniques St-Luc Brussels, Belgium; University La Fe Hospital, 
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Valencia, Spain; Hannover Medical School, Germany; RiMED Foundation Palermo, Italy; 
and Karolinska University Hospital, Sweden. 
 
1.1.4.1 Liver cirrhosis 
Liver transplantation is the only curative treatment for patients with end-stage liver disease. 
Few options exist for patients who are not liver transplantation candidates or for whom an 
organ is not available. In end-stage liver disease patients, hepatocyte transplantation has been 
investigated both with the aim of providing temporary liver support as a bridge to 
transplantation and as a means of improving liver function and quality of life (46). In chronic 
liver disease, the spleen is considered the optimal hepatocyte transplantation site since the 
liver architecture is disturbed and portocaval shunts increase the risk of lung embolization 
during portal infusion. Studies in animal models of liver cirrhosis show that transplantation of 
hepatocytes to the spleen leads to long-term engraftment and improved serum bilirubin, 
plasma ammonia, encephalopathy, and overall survival (47-50).  
Mito et al. performed the first human hepatocyte transplantations for liver cirrhosis. In their 
study, 10 patients underwent liver resection of the left lateral segment and isolated 
hepatocytes were autotransplanted by direct injection into the spleen. Repeated Technetium-
99m labeling revealed transplanted hepatocytes in the spleen at 1 month and 6 months. 
However, the authors concluded that the observed improvement in encephalopathy could not 
be attributed to the transplant (51). Fisher and Strom described a series of 7 patients with liver 
cirrhosis of varying degrees and etiologies (5, 46, 52, 53). They demonstrated engraftment 
and long-term survival of allogenic hepatocytes in the spleen. Four patients were successfully 
bridged to organ transplantation, and a subset of patients showed improvements in 
encephalopathy and blood ammonia. However, the results were inconclusive due to the small 
patient number and the lack of controls.  
 
1.1.4.2 Acute liver failure 
In acute liver failure, hepatocyte transplantation is performed to provide temporary liver 
support to bridge patients until liver transplantation or until native liver regeneration (54). 
Unlike liver transplantation, hepatocyte transplantation has the advantage that it can be 
performed with readily available cryopreserved hepatocytes. Additionally, hepatocyte 
transplantation is reversible and, thus, immunosuppression can be discontinued upon 
recovery of the native liver. To date, 46 patients with acute liver failure of various etiologies 
have been treated with hepatocyte transplantation at 11 different centers worldwide (5, 36, 
45, 46, 52, 53, 55-60). These results have been reported as either case reports or case series. 
Some patients were treated with the intention to bridge to liver transplantation, while others 
were not considered candidates for liver transplantation due to underlying medical 
contraindications. Of the hepatocyte transplanted patients, 27 patients died within 52 days, 10 
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patients were successfully bridged to organ transplantation, and 9 patients recovered without 
organ transplantation. The investigators reported improvements in encephalopathy, cerebral 
edema, coagulopathy, and blood ammonia after hepatocyte transplantation. These results are 
encouraging and are confirmed in animal experiments. However, as these trials were 
performed in small numbers of patients and without adequate controls, it is difficult to draw 
firm conclusions. 
 
1.1.4.3 Inherited metabolic liver diseases 
The most promising clinical hepatocyte transplantation results have been obtained in patients 
with metabolic liver diseases. Inherited metabolic liver diseases are characterized by the 
deficiency of a single hepatic enzyme or protein, which results in hepatic or extrahepatic 
disease. Replacing 5–20% of the missing enzyme is often sufficient to reverse the disease 
state. Preclinical and clinical experience with hepatocyte transplantation for treatment of 
inherited metabolic liver diseases, as well as future challenges of this procedure are 
summarized in the supplemental publication (9).  
 
1.2 LIPOPROTEINS AND APOLIPOPROTEIN E 
Lipoproteins are macromolecules that emulsify hydrophobic lipids, thus enabling their 
transportation in the hydrophilic plasma environment (61). They comprise an outer 
hydrophilic layer and an inner hydrophobic core. The outer layer is composed of amphiphatic 
phospholipids and apolipoproteins, whereas the core consists of triglycerides and cholesteryl 
esters (CE)(62). In addition to their structural function, apolipoproteins serve a metabolic 
function as cofactors of enzymes or as ligands for cell surface receptors, and can be 
exchanged among the lipoprotein particles (61). Apolipoproteins can be divided into five 
main types (A, B, C, D, and E) as well as several subtypes (e.g., A-I, A-II, A-IV; and C-I, C-
II, and C-III) (63). Lipoproteins can be classified according to their density, size, or their 
apolipoproteins (Table 1).  
Table 1 Characteristics of plasma lipoproteins (61). Abbreviations: CM, chylomicron; HDL, high-density 
lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low- density 
lipoprotein. 
 CM VLDL IDL LDL HDL 
Density (g/mL) < 0.95 0.95–1.006 1.006–1.019 1.019–1.063 1.063–1.210 
Diameter (nm) 75–1200 30–80 25–35 18–25 5–12 
Major 
apolipoproteins 
B48,A-I,A-IV, 
E,CI,CII,CIII 
B100, E, 
CI,CII,CIII 
B100,E, 
CI,CII,CIII 
B100 A-I,A-II,CI, 
CII,CIII,E 
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Apolipoprotein E (ApoE) is a 34-kDa apolipoprotein mainly found on chylomicrons, very 
low-density lipoproteins (VLDL), and their remnants, as well as on high-density lipoproteins 
(HDL) (64). This apolipoprotein is mainly produced by hepatocytes but can also be expressed 
by other tissues and cells, with about 20% of serum ApoE produced by extrahepatic sources 
(65, 66). ApoE binds to the LDL receptor (LDLR) and the LDL-receptor-related protein 
(LRP), facilitating hepatic uptake and degradation of its associated lipoprotein (64). Humans 
express three different isoforms of ApoE—E2, E3, and E4—which are the product of three 
alleles (ε2, ε3, and ε4) that each differ by only a single amino acid substitution. Thus, six 
phenotypes are possible—E3/3, E4/3, E3/2, E4/4, E4/2, and E2/2—which occur with varying 
frequencies in different populations (67). This gene polymorphism has several functional 
consequences, including an influence on the level of gene product, e.g., ε2 is associated with 
higher ApoE serum concentrations compared to ε4 (63). The different isoforms also vary in 
their binding capacity to the LDLR, with E2 showing less than 2% of the capacity of E3 and 
E4, resulting in decreased hepatic uptake of its lipoprotein. Consequently, ε2 allele carriers 
exhibit slower clearance of dietary lipids from their circulation (68). Homozygosity for ε2 is 
strongly associated with type III hyperlipoproteinemia, which is characterized by increased 
triglyceride and cholesterol levels, accumulation of chylomicrons and VLDL remnants, and 
premature atherosclerosis (69).  
 
1.2.1 Apolipoprotein E knock out mouse 
Apolipoprotein E-deficient (−/−) mice were simultaneously developed in two different 
laboratories with the purpose of generating a mouse model of atherosclerosis (70, 71). Murine 
cholesterol metabolism substantially differs from that in humans, with mice showing lower 
serum cholesterol concentrations (2.2 mmol/L) that mainly comprise HDL particles. In 
humans, normal blood cholesterol ranges from 4–8 mmol/L and mainly comprises VLDL and 
LDL particles (72). Moreover, due to their rapid hepatic LDL clearance, wild-type mice do 
not develop atherosclerosis even with higher cholesterol ingestion and synthesis (73). 
However, ApoE deficiency results in a murine serum cholesterol concentration of  ~13 
mmol/L on chow diet and a further four-fold increase on a high-fat Western-type diet. These 
mice show a lipoprotein profile characterized by cholesterol accumulation in VLDL and 
chylomicron remnants. ApoE (−/−) mice develop spontaneous atherosclerosis on chow diet 
early in life, and are the most commonly used animal model in atherosclerosis-related 
research (74). Heterozygous ApoE (+/−) mice display normal cholesterol levels and do not 
develop atherosclerosis (70). ApoE replacement in the ApoE (−/−) mouse by gene therapy, 
bone marrow transplantation, or infusion of recombinant ApoE protein results in lipoprotein 
profile normalization and prevention or reversal of atherosclerosis (75-77). Mouse 
atherosclerosis is most commonly  evaluated either by quantifying plaque cross-sectional area 
in aorta sections or by measuring cholesteryl ester content in the aorta as an index of lesion 
development (78). 
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2 AIMS 
 
The general aim of the present thesis was to improve results in clinical hepatocyte 
transplantation. The specific aims of the studies were as follows: 
 
I. To evaluate strategies for short-term storage of human hepatocytes before 
transplantation. 
II. To establish a hepatocyte transplantation model in the ApoE knockout mouse using 
serum apolipoprotein E as a marker of graft function. 
III. To study whether hepatocyte transplantation can correct hypercholesterolemia in the 
ApoE knockout mouse. 
IV. To study the safety and efficacy of partial hepatectomy preconditioning and HLA 
antibody formation in clinical hepatocyte transplantation. 
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3 METHODOLOGY  
 
3.1 ETHICS 
All studies were approved by the regional ethics committee and informed consent from the 
patients and/or patient´s parents were obtained. Animal studies were approved by the ethical 
Committee for Animal Experiments at the Swedish Board for Agriculture.  
 
3.2 HUMAN HEPATOCYTE ISOLATION 
Human hepatocytes were isolated from liver tissue obtained from deceased donors or patients 
undergoing liver transplantation or liver surgery (Paper I & IV). Isolation was performed by 
classical three step collagenase perfusion according to Strom et al. (23). In brief, major 
hepatic vessels were cannulated and perfused with three different solutions. The first solution 
contains ethylene glycol tetraacetic acid (EGTA), an iron chelator, to remove calcium 
disrupting intercellular connections. The second solution consists of an electrolyte solution 
including a buffer to flush out the remaining EGTA as calcium is needed for proper function 
of collagenase. The third solution contains collagenase disrupting the extracellular matrix. In 
this study two different collagenases were used. For in vitro research purposes Collagenase 
XI (Sigma) and for clinical transplant purposes a good manufacturing practice (GMP) 
approved enzyme was used (CIzyme™,Vitacyte, Indianapolis). For optimal function of the 
collagenase the liver was placed in a water bath at 37°C. After 15 – 35 min of digestion the 
liver capsule was cut open and the cell suspension released into ice-cold media solution. 
Thereafter hepatocytes were filtered, washed and purified by low speed centrifugation. 
Hepatocyte viability was assessed by trypan blue exclusion test. Hepatocyte yield is 
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3.4 HEPATOCYTE CHARACTERIZATION  
3.4.1 Plating efficiency 
Plating efficiency measures the capability of isolated hepatocytes to adhere to an extracellular 
matrix. It is expressed as percentage of total cells seeded per well. 7.5 x 105 viable 
hepatocytes were seeded per well of a six-well culture plate. Two hours after plating, medium 
from 3 wells was exchanged with fresh medium and 3 wells were left untouched. After 
overnight culture wells with exchanged media were washed again to remove all unattached 
cells. Plating efficiency was defined as the percentage of protein content in washed wells of 
the protein content in unwashed wells. Protein content was quantified by Bradford assay 
(Bio-Rad Protein Assay kit). 
 
3.4.2 Drug metabolism studies 
Drug metabolism studies were performed to characterize hepatocyte specific function of 
isolated hepatocytes in suspension or after a period of culture. Evaluation of hepatocyte 
specific functions included ammonia metabolism assay, Cyp 450-Glo assays, 7-
Ethoxyresorufin-O-Deethylase (EROD) assay, Testosterone hydroxylation assay, Resorufin 
conjugation. 
 
3.4.3 Ammonia metabolism 
Ammonia metabolism in hepatocytes was evaluated by direct colorimetric quantification of 
ammonia according to Okuda et al. (79). Hepatocytes were exposed to 1mM ammonium 
chloride (NH4Cl) for 2 hours. After deproteinization with 5% Sodium Tungstate solution 
samples were incubated with color reagent solution (4% phenol, 0.015% Sodium 
Nitroprusside, 5% KOH, 28% K2CO3, 3% Sodium Hypochlorite) for 25 min at 37°C and read 
on a spectrophotometer at 560nm. Results were quantified on a standard curve and expressed 
as nmol/min normalized to total protein content. Ammonia metabolism was evaluated in 
hepatocytes in suspension as well as in culture. 
 
3.4.4 Cyp 450-Glo 
Cytochrome P450 enzyme activity for CYP 1A2, 2C9, 3A7, and 3A4 were analyzed with a 
commercially available assay according to the manufacturer´s instructions with minor 
modifications according to Gramignoli et al. (CYP-GLOTM, Promega)(80). The assay is 
based on pro-luminescent substrates that are converted by specific CYP enzyme subtypes 
into a luciferin product, which can be quantified by a second reaction with added luciferase. 
The amount of light is proportional to CYP activity. Luminescence was read with a 
luminometer. Results are expressed as luminescence counting units (LCU)/min and 
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normalized to double-stranded DNA (dsDNA) content. DsDNA was quantified Quant-iTTM 
PicoGreen dsDNA staining kit according to manufacturer´s instructions (Molecular Probes, 
Invitrogen). CYP 450-Glo was used for cells in suspension and in culture with and without 
induction by rifampicin and phenobarbital. 
 
3.4.5 7-Ethoxyresorufin-O-Deethylase (EROD) assay 
EROD assay measures the activity of CYP1A1/2 by the conversion of 7-ethoxyresorufin to 
resorufin. Resorufin is fluorescent and can be quantified on a fluorescent spectrometer. 
Hepatocytes in culture or in suspension were incubated with 7-ethoxyresorufin for 1 hour at 
37°C. Additionally, to study CYP induction hepatocytes in culture cells were treated for three 
days with beta-naphthoflavone (BNF) or vehicle control (DMSO). After incubation media 
was collected and read on a fluorescent spectrometer at excitation wavelength 535 nm and 
emission wavelength of 581 nm. Concentrations were extrapolated from a standard curve and 
expressed as picomole per min normalized to total protein content.  
 
3.4.6 Resorufin conjugation 
Phase II activity was assessed by the conjugation of resorufin. Resorufin was added to 
hepatocytes in suspension and culture for 30min. Media and cells were collected and 
analyzed with the same conditions described for the EROD assay. Resorufin was quantified 
by the decrease in the fluorescent signal interpolated from a standard curve expressed as 
picomole per min normalized to total protein content. 
 
3.4.7 Apoptosis analysis 
3.4.7.1 Caspase 3/7 Activity 
Caspase 3/7 Activity was evaluated with a luminescent, commercially available assay 
according to the manufacturer´s instructions (Caspase-Glo 3/7, Promega). Hepatocytes in 
suspension were incubated with Caspase-Glo reagent for 30 min at room temperature. 
Luminescence was read with a luminometer and results expressed as LCU/min normalized to 
a million of viable hepatocytes. 
 
3.4.7.2 Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) 
Staining 
TUNEL staining was performed on liver tissue and isolated hepatocytes. ApopTag® 
Peroxidase In Situ Apoptosis Detection Kit was used according to manufacturer´s 
instructions (Millipore). TUNEL staining detects DNA fragmentation, a result of apoptosis, 
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by using the enzyme terminal deoxynucleotidyl transferase (TdT) adding labeled 
Deoxyuridine triphosphate (dUTP) to nicks in the DNA. After TUNEL staining slides were 
counterstained with hematoxylin and evaluated under the microscope. Results are expressed 
as percentage of TUNEL-positive hepatocytes of the total number of hepatocytes. 
 
3.4.8 Immunocytochemistry 
Immunocytochemistry was performed on smears of hepatocytes to quantify contamination of 
the hepatocyte graft with non-parenchymal cells. Cell smears were prepared using standard 
cytology techniques. Slides were postfixed with 4% formaldehyde. All reactions were 
performed on an automated Leica Bond-III immunostainer. The following primary antibodies 
were used: CD45 (hematopoietic cell marker), CD31 (marker of endothelial cells), CK18 
(marker of hepatocytes), and CD68 (macrophages/Kupffer cells). Quantification was 
performed under a light microscope by counting more than 800 cells on each slide. 
 
3.5 ANIMALS 
For hepatocyte transplantation experiments female C57bl/6J mice were used as hepatocyte 
donors and female apoE knock out mice on a C57bl/6 background (apoE -/-; B6.129P2-
Apoetm1 Unc N11) were used as recipients (Paper II and III). Animals received normal chow 
diet if not specified otherwise. Blood samples were taken from the tail vein under isoflurane 
anesthesia. Animals were euthanized under isoflurane anesthesia by blood collection from the 
inferior vena cava and organ removal. 
 
3.6 MOUSE HEPATOCYTE ISOLATION 
In contrast to human hepatocyte isolation mouse hepatocyte isolation was performed in situ. 
The inferior vena cava or the portal vein was used for perfusion of the liver. Perfusion 
solutions were the same as for human hepatocyte isolation except that collagenase IV 
(Sigma) was used instead. After digestion cells were filtered and washed by low speed 
centrifugation. 
 
3.7 MOUSE HEPATOCYTE TRANSPLANTATION 
Mouse hepatocytes were resuspended in saline solution containing dextran and heparin. 1 – 2 
million hepatocyte resuspended in 100-200 µl solution were injected into the spleen or 
directly into the liver. 
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3.8 APOE ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
A sandwich ELISA was established to quantify mouse ApoE (Paper II &III). 96 well plates 
were incubated over night with capture antibody (polyclonal goat anti-ApoE, Calbiochem 
178479). Plates were incubated with diluted mouse serum samples. After washing plates 
were incubated with detection antibody (polyclonal rabbit anti-ApoE, PA1- 46367, Thermo 
Scientific Pierce Products). As secondary antibody ALP conjugated goat anti-rabbit IgG was 
used. ALP substrate pNPP (p-nitrophenyl-phosphate) was added before absorbance was 
measured at 405 nm. ApoE concentration was extrapolated from a standard curve with serial 
dilutions of wild type serum. Results are expressed as percentage of wild type. 
 
3.9 APOE GENE EXPRESSION ANALYSIS 
Quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to quantify 
mouse ApoE gene expression in various organs after transplantation. Tissue was 
homogenized and total RNA extracted with Trizol reagent. cDNA was synthesized using 
reverse transcriptase and random hexamer primers. Quantitative PCR was performed with 
TaqMan technique with mouse ApoE and mouse cyclophilin specific primers spanning over 
exon-exon junction. ApoE levels were normalized to cyclophilin expression and expressed as 
percentage of wild type expression.  
 
3.10 LIPID ANALYSIS 
Cholesterol content in serum lipoprotein fractions was analyzed by size exclusion 
chromatography according to Parini et al. (81). Serum lipoproteins were separated over a 
Superose gel column using a pump. The separated lipoproteins were then mixed with 
cholesterol detecting reagents (Roche/Hitachi Diagnostic) and absorbance was measured at 
500nm. Data were collected every 20 seconds. Results were either presented as lipoprotein 
profiles with arbitrary values or the area under the curve was used to calculate the cholesterol 
concentration expressed as mmol/L.  
 
3.11 APOE RNA IN SITU HYBRIDIZATION 
RNA in situ hybridization was used to detect engrafted wild type hepatocytes in ApoE (-/-) 
liver. RNA in situ hybridization uses complementary labeled RNA probes to detect mouse 
ApoE mRNA. In this thesis OCT mounted liver cryosections from transplanted ApoE (-/-) 
mice and controls were evaluated with RNAscope® assay with a customized mouse ApoE 
probe (ID#313271, Advanced Cell Diagnostics, Hayward, CA) according to manufacturer´s 
instructions. Detection was performed by the conversion of DAB (3,3'-Diaminobenzidine) by 
peroxidase labeled probes resulting in a brown color.  
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3.12 HUMAN HEPATOCYTE TRANSPLANTATION 
Human hepatocytes were transplanted by infusion into the portal vein. Access to the portal 
vein was established by open cannulation of the umbilical vein or a mesenteric vein. The tip 
of an intravascular catheter was advanced to the bifurcation of the main portal vein. Correct 
position was verified by fluoroscopy with injection of intravenous contrast. To induce liver 
regeneration patients underwent resection of liver segments 2 and 3 before infusion of 
hepatocytes. Liver resection was only performed with the first hepatocyte transplantation. To 
minimize surgical injury the resection line was placed 1 cm left of the falciform ligament and 
hilus structures were left untouched. Liver parenchyma was transected by cavitron ultrasonic 
surgical aspirator. Blood vessels and bile ducts were divided along the transection lane. In 
this study only fresh and not cryopreserved hepatocytes were used. Hepatocytes were infused 
in an electrolyte solution with addition of 4% human albumin at a concentration of 1-2x 107 
hepatocytes/ml. Infusion was performed with a pump at a flow rate of 1-3ml/min. During the 
infusion portal pressure was continuously measured and flow rate was adjusted accordingly. 
Heparin was given with the hepatocyte graft and thereafter intravenously to obtain an 
activated partial thromboplastin time (aPTT) of 70 – 140s. Doppler ultrasound was performed 
regularly after transplantation to rule out portal thrombosis. Immunosuppression consisted of 
20mg basiliximab on day 0 and 4 and 500 mg of i.v. methylprednisolone on day 0. Thereafter 
steroids were tapered to 5mg prednisolone daily. Tacrolimus was given to maintain trough 
concentrations of 10-13ng/ml the first month and 6-8ng/ml thereafter.  
 
3.13 IMMUNOLOGICAL INVESTIGATION 
3.13.1.1 Evaluation of HLA antibodies 
Complement-dependent cytotoxicity- (CDC) and flow cytometry crossmatch (FACS) were 
performed by the routine clinical immunology laboratory before each hepatocyte 
transplantation. Patients were evaluated before and every 3-4 months after hepatocyte 
transplantation for HLA-antibodies using Luminex-based LABScreen® PRA and Single 
Antigen assay (One Lambda, Inc.). Detection of complement binding anti-HLA antibodies 
was performed by C1q assay with single-antigen flow bead assays (C1qScreenTM, one 
Lambda). Reactivity was normalized for background and expressed as mean fluorescence 
intensity (MFI). MFI values above 1000 were considered positive. 
 
3.13.1.2 Evaluation for autoantibodies 
Patient serum was analyzed by the clinical immunology laboratory for presence of the 
following autoantibodies: Antinuclear antibodies (ANA) against dsDNA, centromere B, 
nucleosomes, Jo1, Ribosomal P, RNP 68, RNP A, Scl-70, Sm, SmRNP, SS-A52, SS-A60, 
SS-B were analyzed by indirect immunofluorescence assay (Immunoconcepts) and multiplex 
ANA assay (BioPlex2200, BioRad). Anti-mitochondrial and Liver specific autoantibodies 
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against SLA/LP, M2, M2-3E, gp210, Sp100, PML, RO52, LKM-1, and LC-1 were analyzed 
by line immunoassay (Euroimmune). Anti-smooth muscle antibodies were evaluated by 
indirect immunofluorescence assay (Kallestad, BioRad). 
 
3.13.1.3 Evaluation of UGT1A1 antibodies 
Patient serum was analyzed for the presence of antibodies against UGT1A1 by ELISA 
according to Seppen et al (82) 
 
3.14 ANALYSIS OF BILIRUBIN CONJUGATES IN BILE 
Bile samples were collected from the patient before hepatocyte transplantation by direct 
puncture of the gallbladder during surgery. After transplantation duodenal bile was collected 
by a nasal duodenal tube and stimulation of bile flow by a meal containing high content of 
protein and fat. Bilirubin conjugates were quantified by HPLC according to Seppen et al (83). 
Bilirubin and bilirubin conjugates were separated on a HPLC column (84). Absorbance of the 
eluate was measured at 450 nm. The identity of the peaks was confirmed by examining the 
spectra. The percentage of bilirubin conjugates was calculated by the area under the curve. 
 
3.15 ANALYSIS OF GROWTH FACTORS AND CYTOKINES 
Serum concentration of hepatocyte growth factor (HGF) was quantified by ELISA (HGF 
Quantikine). Serum epidermal growth factor (EGF), tumor necrosis factor alpha (TNF-alpha) 
and interleukin 6 (IL-6) were analyzed by Luminex (Human cytokine magnetic kit, Merck 
Millipore). 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
At most centers performing hepatocyte transplantation, the hepatocytes are cold stored in a 
preservation solution after isolation until transplantation. This period commonly lasts 1–3 
days, as only a limited number of hepatocytes can be infused during one transplantation event 
due to the increased portal pressure and the risk of portal thrombosis. The method of cold 
storage in UW solution is adopted from preservation of organs for transplantation and has its 
limitations as hepatocytes undergo apoptosis due to loss of cell anchorage (85). Thus, we 
hypothesized that hepatocyte viability would be better preserved by storing several pieces of 
liver tissue and performing repeated hepatocyte isolations rather than storing isolated 
hepatocytes.  
In the current study, we compared traditional cold storage of isolated hepatocytes in UW 
solution to storage of liver tissue with repeated hepatocyte isolations on hepatocyte viability 
and function. Liver tissue was divided into two pieces (Fig 1, Paper I). From one piece 
hepatocytes were isolated directly. These hepatocytes were either characterized immediately 
(Fresh) or analyzed after 48h cold storage in UW (UW cells). The other liver tissue piece was 
stored in UW and hepatocytes were isolated and analyzed after 48h (UW tissue cells).  
Our results show that hepatocyte viability, plating efficiency and CYP activity decreases 
during cold storage of isolated hepatocytes whereas these hepatocyte specific functions are 
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transplantation. We currently schedule our isolations to minimize hepatocyte suspension 
time, and perform repeated isolations when the size and anatomy of the liver tissue is 
suitable. Repeated isolations involve additional cost and labor, but this is compensated by 
improved cell quality. Although not shown in this study the total yield is not decreased by 
this procedure.  
This study has several limitations. The tissue used for hepatocyte isolation does not meet the 
criteria for clinical use, as a majority of the donors were older, showed higher degrees of 
steatosis, and had received neoadjuvant chemotherapy—which are all factors that affect 
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hepatocyte quality after isolation (86-88). Furthermore, additional analysis after 1 day and 3 
days would have been preferable, but the number of analysis time-points was limited by the 
tissue sample sizes. Finally, our study does not address cryopreservation as an alternative 
method of hepatocyte storage. Cryopreservation has the advantage of enabling long-term 
storage, thus allowing more extensive quality testing and scheduled transplantations. 
However, recent experiences from other centers indicate that cryopreservation and thawing 
cause severe hepatocyte damage, substantially reducing viability and function (27, 89, 90). 
 
4.2 PAPER II 
This study aimed to establish a hepatocyte transplantation model in the ApoE knockout 
mouse, with the long-term goal of using this model to study different pretreatment modalities 
to improve donor hepatocyte engraftment and liver repopulation. The ApoE knockout mouse 
was selected because ApoE is mainly produced by hepatocytes. The mouse model is a 
prototype of a metabolic liver disease in which deficiency of a single liver-specific protein 
results in extrahepatic disease (74). It has been used extensively in cardiovascular research  
and is a very well-characterized model. We hypothesized that serum ApoE concentration, 
hepatic ApoE expression, and changes in hypercholesterolemia and lipoprotein profiles could 
be used as graft function markers. We used this model to evaluate whether early 
inflammatory injury—a recognized factor for graft loss during cell transplantation—could be 
modified by peritransplant treatment with methylprednisolone, anakinra, or a combination of 
both (91-94).  
Wild-type hepatocytes isolated from C57bl/6 mice were transplanted into ApoE knockout 
mice by infusion into the spleen. All animals displayed donor hepatocyte engraftment as 
measured by ELISA, and hepatic ApoE mRNA expression at 1–2% of wild-type levels. 
Hepatic ApoE mRNA expression correlated with serum ApoE measurements. We detected 
no difference between the different treatment groups: control, methylprednisolone, anakinra, 
and anakinra + methylprednisolone. In all groups a small decrease in VLDL cholesterol was 
observed, but lipoprotein profiles remained unchanged with accumulation of cholesterol in 
VLDL and LDL particles.  
These results showed that serum ApoE can be used as a marker for donor hepatocyte 
engraftment. Furthermore, the system was shown to be very sensitive as ELISA detected 
serum ApoE levels of less than 0.1%. Our findings also have implications for clinical 
hepatocyte transplantation. A reliable marker of graft function could substantially improve 
clinical hepatocyte transplantation. Moreover, as there are three different isoforms of human 
ApoE, ApoE isoform-specific detection could be used in case of a mismatch between donor 
and recipient. 
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4.3 PAPER III 
In study II, the observed engraftment rates were low (1–2%) as no strong pretreatment was 
used. Although we detected a slight decrease in VLDL cholesterol, hypercholesterolemia and 
lipoprotein profiles were not corrected. In study III, we evaluate whether higher engraftment 
rates would lead to hypercholesterolemia normalization. ApoE (−/−) mice were pretreated 
with retrorsine to give the donor hepatocytes a selective growth advantage. Retrorsine is an 
alkylating agent that induces DNA damage, resulting in long-lasting inhibition of hepatocyte 
cell division. It has been shown to give donor hepatocytes a growth advantage in hepatocyte 
transplantation in rats; however, its efficacy in mice has been questioned in previous studies 
(95). In study III, ApoE (−/−) mice received three intraperitoneal injections of 70 mg/kg 
retrorsine 1 week apart. After 6 weeks, the mice underwent partial hepatectomy followed by 
splenic infusion of wild-type hepatocytes. Control mice were sham transplanted or 
transplanted without retrorsine pretreatment. Animals were monitored weekly with blood 
sampling, and sacrificed 12 weeks after transplantation.   
All retrorsine-pretreated mice showed a continuous increase of serum ApoE levels, reaching 
3.5–55% of wild-type levels after 12 weeks, suggesting donor hepatocyte proliferation. 
Hepatic ApoE mRNA expression correlated with serum ApoE concentrations. In situ 
hybridization of liver cryosections revealed a high degree of donor cell repopulation in 
multiple clusters throughout the liver. All retrorsine-treated mice showed continuous 
improvements in lipoprotein profiles and hypercholesterolemia. After 5–7 weeks, 
hypercholesterolemia and lipoprotein profiles were normalized in retrorsine-treated animals, 
except that HDL cholesterol remained significantly lower compared to wild-type mice. We 
found significantly lower cholesteryl ester in the thoracic aorta among retrorsine-pretreated 
animals compared to controls, suggesting that hepatocyte transplantation also prevented 
atherosclerosis.  
Paper III shows that hepatocyte transplantation can cure the metabolic disease in ApoE (−/−) 
mice. Our findings confirm that retrorsine is effective in mice for increasing repopulation of 
recipient liver. Interestingly, a serum ApoE concentration of 3.5% was sufficient to normalize 
hypercholesterolemia. 
 
4.4 PAPER IV 
The aim of study IV was to establish a clinical hepatocyte transplantation program at the 
Karolinska University Hospital to evaluate the safety and feasibility of partial hepatectomy 
preconditioning. We also monitored the immune response to the hepatocyte graft via serum 
analysis for HLA antibodies.  
Two patients with Crigler-Najjar type I were evaluated at our center. Patient 1 was a 13-year-
old male of Middle Eastern descent, and Patient 2 was an 11-year-old female of mixed 
European and Latin American descent. Both patients had been diagnosed based on elevated 
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unconjugated serum bilirubin, identification of a UGT1A1 mutation, lack of bilirubin 
glucuronides in bile, and non-responsiveness to phenobarbital treatment. Each patient had 
received daily phototherapy of 7–10 hours since birth. At presentation, their serum bilirubin 
concentration ranged from 400–450 µmol/L. These patients were evaluated and scheduled for 
hepatocyte transplantation after receiving informed consent from both the patients and their 
parents.  
Hepatocytes were isolated from liver tissue obtained from deceased organ donors at the 
Livercell laboratory VECURA, Karolinska University Hospital. The isolated hepatocytes 
showed excellent viability and function, as determined by trypan blue staining and analysis of 
Cyp P450 enzyme activity. Portal vein catheters were introduced by cannulation of the 
umbilical vein or a mesenteric vein. Before the first hepatocyte infusion, resection of liver 
segments 2 and 3 was performed to induce liver regeneration and thus repopulation with 
donor hepatocytes. Liver resection was only performed with the first transplantation in each 
patient.  
In both cases, liver resection and hepatocyte transplantation were uncomplicated. Portal 
pressure increased during infusion, but repeated Doppler ultrasound of the liver revealed no 
signs of portal thrombosis. Patient 1 underwent two transplantations from two different 
donors, receiving a total of 11.5 × 109 viable hepatocytes corresponding to 4.2% of the 
theoretical liver mass. Patient 2 underwent one transplantation from one donor, receiving a 
total of 5.3 × 109 viable hepatocytes corresponding to 3.3% of the total liver mass. After 
transplantation, both patients exhibited an initial increase of serum bilirubin, followed by a 
decline to 50% of pretransplant concentrations. Graft function was further verified by 
detection of bilirubin diglucuronides in bile.  
Patient 1 experienced two serious adverse events. At day 7 after transplantation, he presented 
with mycophenolate intoxication with abdominal pain, vomiting, and diarrhea. Then at 212 
days after transplantation, he presented with crusted scabies (norvegica), a severe form of 
scabies seen in immunosuppressed patients. Patient 2 experienced no serious adverse events. 
Serum analysis for growth factors and cytokines revealed increased levels of hepatocyte 
growth factor (HGF) and epidermal growth factor (EGF) after liver resection and hepatocyte 
transplantation, suggesting that liver resection induced expression of mitogenic signals. 
Interestingly, Patient 1 also exhibited a temporal increase of HGF after the second 
transplantation without liver resection.  
Immunological evaluation of both patients before transplantation showed no HLA antibodies. 
Before transplantation, complement-dependent cytotoxicity and FACS cross-match was 
found to be negative for all donors. Every 3–4 months after transplantation, each patient was 
monitored for HLA antibodies using a Luminex-based panel-reactive antigen (PRA) and a 
Single Antigen assay. At day 342 after transplantation, Patient 1 exhibited high levels of 
HLA antibodies, a subset of which were donor specific. This antibody formation was induced 
by discontinuation of immunosuppression due to recurring scabies infection. Patient 2 
showed high levels of HLA antibodies on day 670 while receiving adequate 
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immunosuppressive therapy. In both patients, HLA antibodies development was temporally 
associated with graft loss as determined by increase in total serum bilirubin.  
This study presents two novel observations. Firstly, we demonstrate the safe application of 
partial hepatectomy to improve liver repopulation with donor hepatocytes—a method that has 
been extensively used in animal models to improve engraftment. Secondly, it is the first 
report of de novo donor-specific HLA antibodies after hepatocyte transplantation in 
association with graft loss. The obvious limitation of this study is that only two patients are 
evaluated. Inborn metabolic liver diseases suitable for hepatocyte transplantation are rare and, 
to date, only 10 patients have received hepatocyte transplantation for Crigler-Najjar type I. 
Thus, this report represents an important contribution to the scant literature regarding clinical 
hepatocyte transplantation. Furthermore, although we note an association between DSA 
emergence and graft loss, no causal association can be determined since we were unable to 
perform histopathological evaluation of liver biopsies, which may have shown antibody-
mediated rejection. Nevertheless, HLA antibodies have not been investigated and pre-
transplant cross-matches are not routinely performed in clinical hepatocyte transplantation. 
Our study emphasizes the need for additional studies to elucidate the role of HLA antibodies 
in human hepatocyte transplantation. 
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CONCLUDING REMARKS AND FUTURE CHALLENGES 
 
In conclusion, hepatocyte transplantation is still a technology under development. Results 
presented in this thesis have shed light on some limitations and possible solutions to improve 
outcome in human hepatocyte transplantation:  
 
I. Short-term cold storage of liver tissue with repeated hepatocyte isolations preserves 
hepatocyte viability and function better than cold storage of isolated hepatocytes. 
 
Paper I identifies hepatocyte suspension time as a potentially important factor influencing 
hepatocyte quality. In this study, only one time-point could be investigated. Additional 
studies have been started with the aim of describing the decline of hepatocyte viability and 
function over time, as well as the actual impact on post-transplantation outcome. The broader 
goal of this and future studies is to increase the quality and number of hepatocytes available 
for transplantation.  
Another means of accomplishing this goal is by improving the hepatocyte isolation process. 
Although hepatocyte isolation techniques have advanced over the years since their 
introduction, the current procedure is still based on the original principles. Isolation success 
as determined by viability and yield varies tremendously from day to day, collagenase to 
collagenase, and liver to liver. During harvest and isolation, liver tissue is subjected to several 
periods of cooling and reheating, which negatively impacts hepatocyte quality. The use of a 
suitable enzyme or other method of digestion that could allow temperature to remain constant 
from liver donation throughout isolation and transplantation would certainly improve 
outcome.  
Another challenge is the limited pool of donor tissue. In our clinical program, we addressed 
this issue by splitting donor liver tissue and using the left lateral segment for hepatocyte 
isolation and the extended right lobe for liver transplantation. We are currently investigating 
whether neonatal donors can be used as an alternative source that would not compete with 
whole organ transplantation. Other studies from our group have also shown that liver 
explants from patients with metabolic liver diseases undergoing liver transplantation can be 
used as “domino donors” that yield a new source of good quality hepatocytes (96). Current 
and planned research further aims to evaluate alternative cell sources of hepatocyte-like cells, 
e.g., progenitor cells, amniotic epithelial cells, induced pluripotent stem cells, and embryonic 
stem cells (97, 98).  
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II. Serum ApoE is a sensitive marker of engrafted wild-type hepatocytes in the ApoE 
knockout mouse.  
 
III. Hepatocyte transplantation with retrorsine pretreatment in ApoE knockout mice 
results in robust liver repopulation, normalization of cholesterol metabolism, and 
atherosclerosis prevention. 
 
Clinically relevant animal models are an invaluable tool for studies of hepatocyte 
engraftment, cell loss during transplantation, and techniques to improve engraftment and 
long-term function of transplanted hepatocytes. Papers II and III illustrate the stem cell-like 
potential of adult hepatocytes. In physiological liver regeneration, damaged liver mass is 
regenerated by proliferation of adult hepatocytes, not stem or progenitor cells (10, 97, 99, 
100). Due to their tremendous proliferative potential, transplanted hepatocytes with a growth 
advantage have the ability to repopulate the entire recipient liver. In animal models, such a 
growth advantage can exist due to an underlying disease—as seen in the fumarylacetoacetate 
hydrolase (FAH)-deficient mouse—or can be induced by chemical or radiation pretreatment 
that blocks the proliferative potential of the native hepatocytes (13, 101-104). Successful 
clinical translation of this concept will revolutionize clinical hepatocyte transplantation, 
potentially leading to hepatocyte transplantation replacing liver transplantation for the 
treatment of metabolic liver diseases. Clinical trials have already started to evaluate 
preconditioning with local hepatic irradiation, and the preliminary results are promising 
(105).  
 
IV. Partial hepatectomy combined with hepatocyte transplantation is safe in patients with 
Crigler-Najjar type I, and induces a robust release of hepatocyte growth factor. HLA 
immunization occurs after hepatocyte transplantation, and donor-specific HLA 
antibodies might be involved in hepatocyte allograft rejection. 
Paper IV describes the first clinical application of partial hepatectomy preconditioning, a 
technique that improves hepatocyte engraftment and repopulation in animal models (106-
111). We show that partial hepatectomy induces a robust release of hepatocyte growth factor, 
and that transplantation of less than 5% of the liver mass induces a strong clinical effect. 
However, additional patients must be evaluated before conclusions can be drawn regarding 
the efficacy of this procedure compared to traditional hepatocyte transplantation.  
Paper IV also addresses HLA immunization, with the results suggesting a possible impact of 
donor-specific HLA antibodies on hepatocyte allograft rejection. HLA antibodies are 
associated with inferior outcome following kidney, heart, liver, and islet transplantation, but 
their role has not previously been addressed in the context of hepatocyte transplantation. 
HLA antibody screening or pretransplant cross-matches are rarely reported for hepatocyte 
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transplantations, and there is no consensus on how to manage a pretransplant positive cross-
match, as the relevance of preexisting or de novo HLA antibodies to the hepatocyte allograft 
is not known.  
Since only a limited number of clinical hepatocyte transplantations have been performed to 
date, we plan to conduct a retrospective multicenter study to screen for HLA antibodies in 
stored serum samples of patients who have undergone hepatocyte transplantation. The aim of 
this study is to generate a comprehensive description of HLA antibody formation and of the 
possible associated factors—e.g., prevalence of pretransplant and de novo HLA antibodies, 
relation to transplantation, graft loss, HLA mismatch, numbers of donors, or 
immunosuppressive treatment. In addition to HLA antibodies, future prospective studies 
should routinely examine cellular immunity against the hepatocyte allograft. Ideally, liver 
biopsies should also be performed to learn more about the mechanisms of hepatocyte 
allograft rejection, which could potentially lead to improved immunosuppression protocols in 
clinical hepatocyte transplantation. 
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